当前位置: X-MOL 学术Drug Des. Dev. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
Drug Design, Development and Therapy ( IF 4.8 ) Pub Date : 2022-09-22 , DOI: 10.2147/dddt.s383101
Manhong Xu 1 , Ruiyan Fan 1 , Xiaoe Fan 2 , Yan Shao 1 , Xiaorong Li 1
Affiliation  

Abstract: Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherence to treatment. To reduce the frequency of administration, prolong the time of drug action, and avoid repeated intravitreal injections, the combination of sustained-release materials with anti-VEGF drug therapy has become an emphasis in ophthalmology. In this review, we highlight the current state of anti-VEGF technology, its challenges, and the sustained-release strategies under investigation or being used in clinical practice. Both continuous release and considerable therapeutic effects can be achieved by encapsulating anti-VEGF drugs in sustained-release materials to minimize the number of intravitreal injections. At present, two sustained-release materials are being tested in clinical research, and although basic research shows the strong therapeutic application prospects of extended-release drugs, its challenges mainly involve the discrepancy between the release rates in vitro and the efficiency of the drugs in vivo. Briefly, sustained release of anti-VEGF agents is an advantageous strategy for treating retinal angiogenesis.

Keywords: anti-vascular endothelial growth factor, retinal angiogenesis, anti-VEGF drugs, sustained-release strategies, ranibizumab, bevacizumab


中文翻译:

抗 VEGF 药物的进展和挑战及其在视网膜血管生成中的持续释放策略

摘要:目前,糖尿病性黄斑水肿(DME)和老年性黄斑变性(AMD)等眼部新生血管疾病的治疗主要是反复玻璃体内注射抗血管内皮生长因子(VEGF)药物。虽然它可以保护视力,但重复注射是一种侵入性治疗方式,会导致严重的并发症并降低患者对治疗的依从性。为减少给药频率,延长药物作用时间,避免反复玻璃体内注射,缓释材料与抗VEGF药物治疗的结合成为眼科研究的重点。在这篇综述中,我们重点介绍了抗 VEGF 技术的现状、挑战以及正在研究或临床实践中使用的缓释策略。通过将抗 VEGF 药物包裹在缓释材料中,以最大限度地减少玻璃体内注射的次数,可以实现持续释放和相当大的治疗效果。目前,两种缓释材料正在临床研究中进行测试,虽然基础研究显示缓释药物具有很强的治疗应用前景,但其挑战主要在于体外释放率与药物在体外释放效率之间的差异。体内。简而言之,抗 VEGF 药物的持续释放是治疗视网膜血管生成的有利策略。尽管基础研究表明缓释药物具有很强的治疗应用前景,但其挑战主要在于体外释放率与药物体内效率之间的差异。简而言之,抗 VEGF 药物的持续释放是治疗视网膜血管生成的有利策略。尽管基础研究表明缓释药物具有很强的治疗应用前景,但其挑战主要在于体外释放率与药物体内效率之间的差异。简而言之,抗 VEGF 药物的持续释放是治疗视网膜血管生成的有利策略。

关键词:抗血管内皮生长因子,视网膜血管生成,抗VEGF药物,缓释策略,雷珠单抗,贝伐单抗
更新日期:2022-09-21
down
wechat
bug